Target Price | $34.17 |
Price | $23.80 |
Potential |
43.57%
register free of charge
|
Number of Estimates | 21 |
21 Analysts have issued a price target Apellis Pharmaceuticals, Inc. 2026 .
The average Apellis Pharmaceuticals, Inc. target price is $34.17.
This is
43.57%
register free of charge
$63.00
164.71%
register free of charge
$19.19
19.37%
register free of charge
|
|
A rating was issued by 27 analysts: 18 Analysts recommend Apellis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Apellis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
43.57%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 781.37 | 954.11 |
97.02% | 22.11% | |
EBITDA Margin | -20.88% | 11.50% |
83.93% | 155.07% | |
Net Margin | -25.32% | -7.01% |
81.00% | 72.32% |
22 Analysts have issued a sales forecast Apellis Pharmaceuticals, Inc. 2025 . The average Apellis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Apellis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Apellis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Apellis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Apellis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.60 | -0.53 |
64.04% | 66.88% | |
P/E | negative | |
EV/Sales | 3.24 |
22 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast for earnings per share. The average Apellis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Apellis Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
Raymond James |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Jul 29 2025 |
Analyst Rating | Date |
---|---|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 26 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 04 2025 |
Locked
Raymond James:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Aug 01 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Jul 29 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.